Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

Ferring Pharmaceuticals112 enrolled

Overview

Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.

Study Type

OBSERVATIONAL

Enrollment

112

Conditions

Advanced Hormone Sensitive Prostate Cancer

Interventions

degarelixDRUG

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer Exclusion Criteria: * Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded * Planned intermittent or short-term (\< 12 months) degarelix treatment * Planned addition of, or switch to another form of androgen deprivation therapy during the study

Locations (1)

Groene Hart Ziekenhuis (there may be other sites in this country)

Gouda, Netherlands

Outcomes

Primary Outcomes

Cardiovascular event rate in hormone naïve prostate cancer patients with cardiovascular comorbidity at baseline, treated with degarelix in daily practice

Time frame: Up to 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.